Revelation Biosciences’ Gemini induces significant increases in IL-10

Revelation Biosciences announced statistically significant, dose dependent increases of interleukin-10, or IL-10, in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the positive topline data from the Phase 1 clinical study of Gemini released on June 24. It was found that Gemini induced statistically significant, dose dependent changes in circulatory IL-10 at 2 hours post-dose, with a p-value of less than 0.05 or greater, at each of the low, mid, and high dose levels. The change in IL-10 observed for treatment groups relative to placebo, were a 27-fold increase, 162-fold increase, and 309-fold increase for the low, mid, and high dose groups, respectively. IL-10 is a potent anti-inflammatory protein that downregulates pro-inflammatory cytokines and is an active contributor to initiating reduction of inflammation. The observed increase of IL-10 in humans is consistent with prior preclinical studies. This demonstrates the potential for Gemini in target indications, including prevention of AKI following cardiac surgery.